Biotech Industry Examiner’s Post

Our CEO Samir Khleif sat down with Rebecca Torrence from Business Insider to share progress on GIM-122's clinical trial, our first-in-class pipeline, and our $75 million in Series A funding, co-led by General Catalyst and Parker Institute for Cancer Immunotherapy. Read the full article to learn how our novel biology is pioneering breakthroughs in cancer and autoimmune drugs: https://bit.ly/3vsRZMR #novelbiology #Georgiamune

Sweden’s NEOGAP Therapeutics receives €500K grant to advance personalized cancer immunotherapy analysis NEOGAP Therapeutics AB, a Stockholm-based biotech company, has secured nearly €500K (SEK 5 million) in funding from Eurostars for a collaboration project with the French biotech company Okomera. NEOGAP is developing pTTL, a personalized cell therapy utilizing modified proteins to activate the immune system against cancer cells, currently undergoing phase I/II clinical trials for colorectal cancer. The funding will enhance the development of an analysis method for T-cell activity against the patient’s tumor, in collaboration with Okomera, aiming to predict the efficacy of NEOGAP’s therapy. https://lnkd.in/d9aZabVu #funding #nordicmade #sweden #healthtech #deeptech #startups #trending

Exciting breakthrough in cancer research: Matheus dos Santos Dias challenges the conventional approach by exploring a novel strategy to combat cancer cells. His innovative method involves stimulating cancer cells to exhaust them, disrupting their ability to evade treatment effectively. With promising results in preclinical studies, this paradigm-shifting approach could revolutionize cancer therapy. Join us in reshaping the future of cancer treatment!

Edgewood Oncology secures $20M in Series A funding backed by Alta Partners to advance the clinical trials of the BTX-A51's groundbreaking cancer treatment. Invented by Prof. Yinon Ben Neriah, BTX-A51, a revolutionary multi-kinase inhibitor developed at The Hebrew University of Jerusalem, is gaining momentum in cancer treatment. With promising results in AML and solid tumors, this partnership marks a significant leap forward in cancer therapy. "Edgewood Oncology that is focused on delivering BTX-A51 to patients with hematologic malignancies and genetically-defined solid tumors will make a significant impact on human society. The current financing will advance the clinical development of BTX-A51 in acute myeloid leukemia (AML) and a precision medicine approach to breast cancer. We support their cause deeply and believe their findings will maximize the treatment opportunities available to battle cancers,” says Dr. Itzik Goldwaser, President & CEO of Yissum, the Technology Transfer Company of the Hebrew University in Jerusalem. Ariela Markel, VP of Business Development, Healthcare, and Lani Dodiuk Questembert, the Deputy General Counsel at Yissum, worked on licensing this innovation. Stay connected for further updates as we continue to push the boundaries in the realm of healthcare - https://bit.ly/3vsN1j8 #Innovation #BTXA51 #CancerTreatment

In a monumental leap forward in cancer therapeutics, Defence Therapeutics unveils a groundbreaking achievement with AccuTOX®. This advanced formulation, strategically designed to target lung-established tumours, marks a significant milestone in the relentless battle against cancer. AccuTOX®, an optimised derivative of the Accum® molecule, has showcased remarkable therapeutic properties, demonstrating its efficacy across various murine and human cancer cell lines. This breakthrough promises a paradigm shift in cancer treatment methodologies, heralding hope for patients grappling with diverse forms of the disease. Find out more below. #LungCancer #CancerTreatment #CancerResearch https://bit.ly/41Upnrr

As we move into 2024, it is conceivable that personalized medicine will become the standard in cancer treatment. It's a pleasure to see so many innovative therapies and leaders mark their stamp on the industry. Malcome Brenner - Baylor College of Medicine Phil Greenberg - Fred Hutchinson Cancer Center John Maher - Leucid Bio Victoria Zazulina - Merck Group Robert Hariri, MD, PhD - Celularity Inc. Christopher A. Klebanoff, - Emory University Kyle Holen - Moderna Lars Nieba - Engimmune Therapeutics Catherine Pickering - iOnctura Carl June - University of Pennsylvania Friedrich Graf Finckenstein - Iovance Biotherapeutics, Inc. Biotherapeutics Steven Rosenberg - National Cancer Institute (NCI) Cancer Institue James Allison - MD Anderson Cancer Center Daniel Chen, M.D. Ph.D. - Physician-Scientist, Cancer Immunotherapy #artificialintelligence #cancer #cancerresearch #crispr #geneediting #immunotherapy #immunooncology #cart #precisionmedicine #personalizedmedicine #biotech #oncologists #antibodydrugconjugates #radiopharmaceuticals

Finland’s TILT Biotherapeutics gets $2M grant from US Department of Defense for ovarian cancer immunotherapy research Helsinki-based biotech company TILT Biotherapeutics Ltd has been awarded a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project focused on ovarian cancer immunotherapy research. The project aims to evaluate the safety and efficacy of TILT-123, the company’s lead clinical program, in combination with pembrolizumab in platinum-resistant/refractory ovarian cancer patients. TILT-123 is an oncolytic adenovirus armed with two human cytokines that boost the patient’s immune response to better target and destroy cancer cells. The grant will support TILT Biotherapeutics’ efforts to develop new therapies for ovarian cancer, a disease with a critical need for improved treatments. TILT-123 is currently being investigated in international clinical trials, and the grant from the DOD marks a significant milestone in advancing these therapies to address the high unmet medical need in ovarian cancer. https://lnkd.in/dK573Dhi #nordicmade #finland #funding #grant #deeptech #healthtech #medtech #startups #cancerresearch #trending

🚀 Unveiling a Game-Changer in Cancer Therapy! 🚀 Bill Tansey's lab is pushing boundaries with a groundbreaking discovery in cancer treatment. Their recent work targets a key protein, WDR5, pivotal in cancer cell growth. By honing in on a specific site within WDR5, the newly developed WINi inhibitors show promising results against several cancer types in early testing. This innovative approach not only halts cancer cell proliferation but triggers a cascade leading to cell death. With potential clinical trials on the horizon, this breakthrough could redefine cancer treatment strategies and offer new hope where current therapies fall short. #CancerResearch #InnovationInMedicine #Healthcare #WINi 🧬💊

Antibody-drug conjugates (ADCs) have emerged as a promising approach in cancer treatment, offering targeted delivery of potent drugs to cancer cells while minimizing damage to healthy tissues. However, challenges remain in optimizing their efficacy and tolerability. At Zymeworks, our researchers are developing next-generation #ADCs designed to achieve robust anti-tumor activity. Advances in technology and understanding of ADCs offer opportunities to improve their efficacy and tolerability, both as monotherapy and in combination with other cancer treatments. The coordinated design and optimization of ADCs holds promise for providing clinical benefits to cancer patients, and the potential for a positive outcome. Learn more in this article from BioSpace authored by our Chief Scientific Officer Paul Moore, PhD: https://lnkd.in/e44Y5y9s #AACR24

Study Finds Hundreds of Overlooked Cancer Drug Targets Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be used to develop new drug therapies. The findings – published in the journal Cancer Cell – came from a systematic look at ‘multi-omic’ information on 930 cell lines taken from 27 different tumor types, including breast, lung, and ovarian cancers, backed up by machine learning technology. The new paper covers the second iteration of the dependency map, which was first published in 2019 and provides a “panoramic view of what enables cancer cells to grow and survive,” according to the scientists. https://lnkd.in/e-WHGu_R #aspenalert #biotech #bioprocess